Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease requiring early, aggressive management to prevent irreversible joint damage and disability. In the United Kingdom, clinicians primarily rely on two national evidence-based guidelines: the National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN). While both aim to standardise and improve care, their approaches can differ in key areas. This comparison for 2025 outlines the similarities and crucial differences between the NICE NG100 (last updated July 2020) and SIGN 123 (published 2011, still current) guidelines for the management of RA, providing a practical, UK-focused overview for clinicians.
See how this translates to practice: Explore our Clinical governance features, visit the Patient Safety Hub, or review Clinical Safety & Assurance for enterprise rollout.
Diagnosis and Initial Assessment
NICE NG100
NICE provides a clear, pragmatic pathway for non-specialists, emphasising rapid referral.
- Referral Criteria: Advises referral to a rheumatologist if persistent synovitis is suspected (lasting more than 4-6 weeks) in any joint, with an unexplained onset before age 16. It explicitly states not to wait for a positive rheumatoid factor or radiographic changes.
- Diagnostic Tools: While acknowledging the 2010 ACR/EULAR classification criteria, NICE does not mandate their use for diagnosis in a clinical setting, focusing instead on clinical suspicion.
- Baseline Assessment: Recommends a core set of assessments at diagnosis: disease activity (e.g., DAS28), functional ability (e.g., HAQ), presence of erosions, rheumatoid factor and anti-CCP antibodies, and comorbidities.
SIGN 123
SIGN's guidance is more closely aligned with formal classification criteria.
- Referral & Diagnosis: Strongly recommends using the 1987 ACR criteria for diagnosis (the standard at the time of publication). It advises early referral for anyone with ≥3 swollen joints and bilateral compression tenderness of the metatarsophalangeal joints.
- Investigations: Places significant emphasis on anti-CCP antibodies, stating they have "high diagnostic specificity." Like NICE, it recommends RF, acute phase reactants, and baseline X-rays of hands and feet.
Key Difference & Practical Takeaway
The major difference lies in the threshold for referral. NICE's "persistent synovitis" is a lower threshold than SIGN's "≥3 swollen joints." The NICE approach is designed to minimise delays in referral from primary care. In practice, most UK services follow the NICE principle of early referral based on clinical suspicion rather than strict criteria.
Pharmacological Treatment Strategy
NICE NG100
NICE advocates for a treat-to-target (T2T) strategy, aiming for a state of clinical remission (DAS28 < 2.6) or low disease activity, with regular 1-3 monthly reviews until the target is met.
- First-line: Recommends a combination of DMARDs (typically methotrexate + sulfasalazine + hydroxychloroquine) as first-line therapy for active disease, plus short-term glucocorticoids. Methotrexate is the anchor drug.
- Biologics & Targeted Therapies: Access to biologic DMARDs (TNF inhibitors, rituximab, abatacept, tocilizumab) and targeted synthetic DMARDs (e.g., JAK inhibitors) is governed by strict NICE Technology Appraisal (TA) criteria. Generally, patients must have failed at least two conventional DMARDs (including methotrexate) and have a high disease activity (usually DAS28 > 5.1).
- Sequencing: After failing a first biologic, guidelines direct clinicians to subsequent lines of therapy based on specific TAs, which may include alternative biologics or JAK inhibitors.
SIGN 123
SIGN's older publication date means it does not formally incorporate the T2T paradigm or newer drug classes like JAK inhibitors.
- First-line: Recommends starting a single DMARD (e.g., methotrexate) promptly, with consideration for combination therapy in those with poor prognostic factors.
- Biologics: Recommends anti-TNF therapy for patients with active disease despite adequate trials of at least two DMARDs, including methotrexate. Its guidance on subsequent biologic options is less detailed than NICE's due to the evolution of TAs post-2011.
Key Difference & Practical Takeaway
The most significant difference is the treatment strategy and first-line approach. NICE's T2T strategy with combination DMARDs reflects modern, aggressive management. SIGN's step-up approach is considered less intensive by today's standards. In UK practice, the NICE T2T model is the standard of care. The choice of specific advanced therapies is almost entirely driven by NICE Technology Appraisals, which are UK-wide and thus supersede the older SIGN recommendations.
Special Situations and Comorbidities
Pregnancy and Breastfeeding
- NICE: Provides detailed advice. Recommends sulfasalazine, hydroxychloroquine, and azathioprine as DMARDs that can be continued. Methotrexate and leflunomide must be stopped prior to conception. Corticosteroids can be used at the lowest effective dose.
- SIGN: Offers similar, though less extensive, guidance on stopping teratogenic DMARDs pre-conception.
Safety Monitoring and Comorbidities
- NICE: Has a strong focus on comorbidity management, including annual cardiovascular risk assessment, screening for osteoporosis, and management of infection risk (emphasising pneumococcal and annual influenza vaccination).
- SIGN: Also addresses cardiovascular risk and infection risk but lacks the detailed annual review structure recommended by NICE.
Practical Takeaway
For managing complex situations like pregnancy, NICE provides more contemporary and comprehensive guidance. Its emphasis on structured annual review for comorbidities is a crucial part of holistic RA management that all clinicians should implement.
Practical Clinical Flow for 2025
The following flow represents a synthesis of current best practice, heavily weighted towards the NICE guideline, which is more up-to-date.
- Primary Care: Suspect RA in a patient with persistent synovitis (>4-6 weeks). Do not delay referral for serology or X-rays. Refer urgently to rheumatology.
- Rheumatology Assessment: Confirm diagnosis (using clinical judgement and 2010 ACR/EULAR criteria). Perform baseline assessments (DAS28, HAQ, RF/anti-CCP, X-rays).
- Treatment Initiation: Start a treat-to-target strategy. First-line: Combination conventional DMARDs (e.g., methotrexate + sulfasalazine + hydroxychloroquine) + short-term glucocorticoids. Agree a disease activity target (e.g., DAS28 < 2.6) with the patient.
- Monitoring & Escalation: Review disease activity every 1-3 months. If target not met, optimize DMARD doses or switch/combine DMARDs.
- Advanced Therapy: If disease remains active despite two csDMARDs (including methotrexate), assess for eligibility for biologic or targeted synthetic DMARDs as per NICE TA guidance. Repeat T2T monitoring.
- Long-term Management: Once target is achieved, maintain on effective therapy with less frequent monitoring. Conduct an annual review including CVD risk, bone health, and vaccination status.
Frequently Asked Questions (FAQs) for Clinicians
1. Which guideline should I follow in Scotland?
While SIGN originates in Scotland, its RA guideline (SIGN 123) is outdated. NHS Scotland clinicians primarily follow the NICE guideline (NG100) for the overall management strategy, as it is more comprehensive and reflects current evidence. NICE Technology Appraisals are also adopted across Scotland.
2. What is the single most important difference between NICE and SIGN?
The treatment strategy. NICE mandates a proactive "treat-to-target" approach with combination DMARDs, whereas the older SIGN guideline suggests a more gradual step-up with single DMARDs. The T2T strategy is proven to yield better long-term outcomes.
3. How do I access biologic therapies for my patients?
Access is determined by NICE Technology Appraisals (TAs), not the core NG100 or SIGN 123 guidelines. You must check the specific TA for each drug (e.g., TA715 for certain JAK inhibitors) to confirm eligibility criteria, which typically require failure of two csDMARDs and high disease activity.
4. The SIGN guideline is from 2011. Is any of it still relevant?
Yes, the principles of early diagnosis, use of DMARDs, and the importance of methotrexate remain valid. However, for detailed treatment strategy, sequencing, and management of special situations, NICE NG100 is the definitive and relevant guide.
5. What about drug monitoring and safety?
Both guidelines emphasise safety monitoring for DMARDs. In practice, local NHS Trust protocols for blood monitoring (e.g., for methotrexate, leflunomide) are followed. NICE's stronger emphasis on annual comorbidity review is a key best practice addition.
Source Links
- NICE Guideline NG100 (July 2020): Rheumatoid arthritis in adults: management
- NICE Evidence Search: For finding current Technology Appraisals (TAs)
- SIGN Guideline 123 (2011): Management of early rheumatoid arthritis (PDF)
- BSR Biologics Registers: British Society for Rheumatology (For safety data on advanced therapies).